An HER2-Displaying Virus-Like Particle Vaccine Protects from Challenge with Mammary Carcinoma Cells in a Mouse Model.

AddaVax Poly (I:C) baculovirus–insect cell expression vector system (BEVS) cancer vaccine glycoengineering human epidermal growth factor receptor-2 (HER2) virus-like particles (VLPs)

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
20 May 2019
Historique:
received: 04 04 2019
revised: 10 05 2019
accepted: 15 05 2019
entrez: 30 5 2019
pubmed: 30 5 2019
medline: 30 5 2019
Statut: epublish

Résumé

Human epidermal growth factor receptor-2 (HER2) is upregulated in 20% to 30% of breast cancers and is a marker of a poor outcome. Due to the development of resistance to passive immunotherapy with Trastuzumab, active anti-HER2 vaccination strategies that could potentially trigger durable tumor-specific immune responses have become an attractive research area. Recently, we have shown that budded virus-like particles (VLPs) produced in

Identifiants

DOI: 10.3390/vaccines7020041 PMID: 31137559 PMC: PMC6631560
pubmed: 31137559
pii: vaccines7020041
doi: 10.3390/vaccines7020041
pmc: PMC6631560
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Austrian Science Fund FWF
ID : W 1224
Pays : Austria

Déclaration de conflit d'intérêts

A.G.-S. is the inventor of patents owned by the Icahn School of Medicine related to the treatment of cancer. All of the other authors declare that they have no conflicts of interest.

Références

J Immunol. 2000 Nov 1;165(9):5133-42
pubmed: 11046045
Cancer Res. 2001 Jun 15;61(12):4744-9
pubmed: 11406546
Somat Cell Mol Genet. 2002 Nov;27(1-6):65-74
pubmed: 12774941
Mol Immunol. 2005 Feb;42(2):259-77
pubmed: 15488613
N Engl J Med. 2005 Oct 20;353(16):1659-72
pubmed: 16236737
Immunity. 2006 Jan;24(1):19-28
pubmed: 16413920
Immunology. 2006 Jan;117(1):11-21
pubmed: 16423036
Nat Methods. 2006 Dec;3(12):1021-32
pubmed: 17117155
Virology. 2009 Jan 5;383(1):12-21
pubmed: 18986663
Lancet. 2009 Feb 21;373(9664):673-83
pubmed: 19231634
Mol Biotechnol. 2010 Jul;45(3):226-34
pubmed: 20300881
Expert Rev Vaccines. 2010 Oct;9(10):1149-76
pubmed: 20923267
J Virol. 1990 Dec;64(12):5695-700
pubmed: 2173762
Expert Rev Vaccines. 2011 Sep;10(9):1281-9
pubmed: 21919618
N Engl J Med. 2011 Oct 6;365(14):1273-83
pubmed: 21991949
PLoS One. 2012;7(4):e34226
pubmed: 22485160
Mol Biotechnol. 2013 Jan;53(1):92-107
pubmed: 23001867
Vaccine. 2013 Jul 18;31(33):3363-9
pubmed: 23684834
J Virol. 2014 Jun;88(11):6368-79
pubmed: 24672031
Cancer Metastasis Rev. 2015 Mar;34(1):157-64
pubmed: 25712293
Clin Med Insights Oncol. 2016 Mar 28;10(Suppl 1):21-30
pubmed: 27042153
J Chromatogr A. 2016 Jul 15;1455:93-101
pubmed: 27286649
Cancer Gene Ther. 2017 Apr;24(4):175-179
pubmed: 28186087
Lancet. 2017 Mar 25;389(10075):1195-1205
pubmed: 28215665
Anal Bioanal Chem. 2017 Apr;409(10):2519-2530
pubmed: 28271226
Protein Expr Purif. 2017 Aug;136:27-38
pubmed: 28619527
Oncoimmunology. 2018 Jan 5;7(3):e1408749
pubmed: 29399414
Vaccines (Basel). 2018 Feb 11;6(1):null
pubmed: 29439476
Nat Rev Cancer. 2018 Apr;18(4):240-254
pubmed: 29497146
Int J Cancer. 2018 Nov 1;143(9):2126-2132
pubmed: 29693245
Vaccines (Basel). 2018 Sep 20;6(4):null
pubmed: 30241300
Cancer. 2018 Dec 1;124(23):4455-4466
pubmed: 30291791
Cancer Immunol Res. 2018 Dec;6(12):1486-1498
pubmed: 30327365
Appl Microbiol Biotechnol. 2018 Dec;102(24):10457-10468
pubmed: 30334089
Immunol Invest. 2019 May;48(4):355-366
pubmed: 30430891
Curr Opin Biotechnol. 2018 Dec 13;60:17-28
pubmed: 30554064
Science. 1987 Jan 9;235(4785):177-82
pubmed: 3798106
In Vitro. 1977 Apr;13(4):213-7
pubmed: 68913
J Exp Med. 1995 Aug 1;182(2):389-400
pubmed: 7629501
Curr Opin Immunol. 1998 Feb;10(1):50-5
pubmed: 9523111
J Exp Med. 1998 Aug 3;188(3):589-96
pubmed: 9687535

Auteurs

Lisa Nika (L)

Department of Biotechnology, University of Natural Resources and Life Sciences, Muthgasse 18, 1190 Vienna, Austria. lisa.nika@boku.ac.at.

Sara Cuadrado-Castano (S)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, 1468 Madison Avenue, New York, NY 10029, USA. sara.cuadrado@mssm.edu.
Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. sara.cuadrado@mssm.edu.

Guha Asthagiri Arunkumar (G)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, 1468 Madison Avenue, New York, NY 10029, USA. guha.asthagiri-arunkumar@icahn.mssm.edu.
Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. guha.asthagiri-arunkumar@icahn.mssm.edu.

Clemens Grünwald-Gruber (C)

Department of Chemistry, Division of Biochemistry, University of Natural Resources and Life Sciences, Muthgasse 18, 1190 Vienna, Austria. clemens.gruber@boku.ac.at.

Meagan McMahon (M)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, 1468 Madison Avenue, New York, NY 10029, USA. meagan.mcmahon@mssm.edu.

Krisztina Koczka (K)

Department of Biotechnology, University of Natural Resources and Life Sciences, Muthgasse 18, 1190 Vienna, Austria. krisztina.koczka@boku.ac.at.
ACIB-Austrian Centre of Industrial Biotechnology, Muthgasse 11, 1190 Vienna, Austria. krisztina.koczka@boku.ac.at.

Adolfo García-Sastre (A)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, 1468 Madison Avenue, New York, NY 10029, USA. adolfo.garcia-sastre@mssm.edu.
Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. adolfo.garcia-sastre@mssm.edu.
Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. adolfo.garcia-sastre@mssm.edu.

Florian Krammer (F)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, 1468 Madison Avenue, New York, NY 10029, USA. florian.krammer@mssm.edu.

Reingard Grabherr (R)

Department of Biotechnology, University of Natural Resources and Life Sciences, Muthgasse 18, 1190 Vienna, Austria. reingard.grabherr@boku.ac.at.

Classifications MeSH